Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer

Journal of Urology

Volumn 187, Issue 4, 2012, Pages 1195-1199

  Hendricksen, K ^a   Cornel, E B ^b   De Reijke, T M ^c   Arentsen, H C ^a   Chawla, S ^d   Witjes, J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Twente Hospital Group   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Spectrum Pharmaceuticals   (United States)

Author keywords

administration; apaziquone; drug therapy; intravesical; urinary bladder neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; APAZIQUONE; BCG VACCINE;

ADULT; ARTICLE; BACTERIAL CYSTITIS; BLADDER CANCER; BLADDER SURGERY; BODY WEIGHT; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; CYSTOSCOPY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INSTILLATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATURIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NONMUSCLE INVASIVE BLADDER CANCER; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT DURATION; URGE INCONTINENCE; URINARY TRACT INFECTION; URINE CULTURE; URINE INCONTINENCE;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AZIRIDINES; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INDOLEQUINONES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSPECTIVE STUDIES; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84858704170     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.11.101     Document Type: Article

References (25)

1. Z. Kirkali, T. Chan, M. Manoharan Bladder cancer: epidemiology, staging and grading, and diagnosis Urology 66 2005 4
2. M.C. Hall, S.S. Chang, G. Dalbagni Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update J Urol 178 2007 2314
3. M. Babjuk, W. Oosterlinck, R. Sylvester Guidelines on non-muscle invasive bladder cancer (TaT1 and CIS) European Association of Urology Guidelines, 2011 2011 Drukkerij Gelderland bv Arnhem 1 36 chapt 1
4. R.J. Sylvester, A.P. van der Meijden, W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466
5. J.A. Witjes, P.S. Kolli Apaziquone for non-muscle invasive bladder cancer: a critical review Expert Opin Investig Drugs 17 2008 1085
6. A.G. van der Heijden, G. Verhaegh, C.F. Jansen Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study J Urol 173 2005 1375
7. A.G. van der Heijden, P.M. Moonen, E.B. Cornel Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response J Urol 176 2006 1349
8. K. Hendricksen, A.G. van der Heijden, E.B. Cornel Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer World J Urol 27 2009 337
9. L.H. Sobin, I.D. Fleming TNM Classification of Malignant Tumors, fifth edition (1997) Union Internationale Contre le Cancer and the American Joint Committee on Cancer Cancer 80 1997 1803
10. F.K. Mostofi, H. Torloni, L.H. Sobin Histological typing of urinary bladder tumours International Classification of Tumors 10 1973 World Health Organization Geneva
11. W. Oosterlinck, B. Lobel, G. Jakse Guidelines on bladder cancer Eur Urol 41 2002 105
12. L.D. Vainchtein, H. Rosing, D. Mirejovsky Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin given intravesically Rapid Commun Mass Spectrom 22 2008 462
13. S.R. Heritier, V.J. Gebski, A.C. Keech Inclusion of patients in clinical trial analysis: the intention-to-treat principle Med J Aust 179 2003 438
14. I. Berrum-Svennung, T. Granfors, S. Jahnson A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences J Urol 179 2008 101
15. S. Gudjónsson, L. Adell, F. Merdasa Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study Eur Urol 55 2009 773
16. K. Hendricksen, W.P. Witjes, J.G. Idema Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer Eur Urol 53 2008 984
17. R.J. Sylvester, W. Oosterlinck An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: has the evidence changed? Eur Urol 56 2009 43
18. J.A. Witjes, J. Palou, M. Soloway Clinical practice recommendations for the prevention and management of intravesical therapy-associated events Eur Urol Suppl 7 2008 667
19. J.B. Thrasher, E.D. Crawford Complications of intravesical chemotherapy Urol Clin North Am 19 1992 529
20. A.P. van der Meijden, M. Brausi, V. Zambon Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial J Urol 166 2001 476
21. A. Bohle, F. Balck, J. von Weitersheim The quality of life during intravesical bacillus Calmette-Guerin therapy J Urol 155 1996 1221
22. C. Bouffioux, A. van der Meijden, K.H. Kurth Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions) Prog Clin Biol Res 378 1992 29
23. P. Workman, M. Binger, K.L. Kooistra Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents Int J Radiat Oncol Biol Phys 22 1992 713
24. H.L. McLeod, M.A. Graham, S. Aamdal Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9 EORTC Early Clinical Trials Group Eur J Cancer 32A 1996 1518
25. R.M. Phillips, P.B. Hulbert, M.C. Bibby In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity Br J Cancer 65 1992 359